914348-10-0

Usage

Uses

2-(Trifluoromethyl)pyrimidine-4-carboxamide is used as pharmaceutical intermediate.

InChI:InChI=1/C17H9F5N2O2/c1-24-7-6-10(23-24)8-2-4-9(5-3-8)17(25)26-16-14(21)12(19)11(18)13(20)15(16)22/h2-7H,1H3

Upstream product

• 1514-96-1 4-chloro-2-(trifluoromethyl)pyrimidine 
• 878745-51-8 methyl 2-(trifluoromethyl)pyrimidine-4-carboxylate 

Downstream Products

• 916210-03-2 2-(trifluoromethyl)pyrimidine-4-carbonitrile 

Relevant academic research and scientific papers

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.